Whim Syndrome With Cxcr4 Mutation Therapeutics
1. Xolremdi patent expiration
Treatment: Treatment of patients 12 years and older with warts, hypogammaglobulinemia, infections, and myelokathexis (whim) syndrome
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11219621 | X4 PHARMS | Methods for treating immunodeficiency disease |
Dec, 2036
(10 years from now) | |
| US10610527 | X4 PHARMS | Methods for treating immunodeficiency disease |
Dec, 2036
(10 years from now) | |
| US11045461 | X4 PHARMS | Compositions of CXCR4 inhibitors and methods of preparation and use |
Dec, 2038
(12 years from now) | |
| US10953003 | X4 PHARMS | Methods for treating cancer |
Dec, 2036
(10 years from now) | |
| US12115156 | X4 PHARMS | Compositions of CXCR4 inhibitors and methods of preparation and use |
Dec, 2038
(12 years from now) | |
| US10548889 | X4 PHARMS | Compositions of CXCR4 inhibitors and methods of preparation and use |
Dec, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 26, 2029 |
| Orphan Drug Exclusivity(ODE-480) | Apr 26, 2031 |
Drugs and Companies using MAVORIXAFOR ingredient
NCE-1 date: 26 April, 2028
Market Authorisation Date: 26 April, 2024
Dosage: CAPSULE
More Information on Dosage
XOLREMDI family patents
